What is BrioVAD?
BrioVAD is a tiny, metal pump about the size of a ping‑pong ball. It sits inside a showroom in Suzhou Industrial Park, Jiangsu province, and is connected to a power source and special biomimetic tubes. Inside, a metallic impeller floats in the middle, levitated by magnets, and spins at high speed without touching any surfaces.
How the pump works
- Magnetic levitation keeps the impeller suspended, so there is no mechanical wear.
- The impeller pushes blood through the tubes, mimicking the natural pumping action of a heart.
- Because the motor is separate from the levitation unit, the device can be small while still having a large rotor that turns slowly enough to be gentle on blood.
Why magnetic levitation matters
Traditional artificial hearts use bearings or fluids that can damage blood cells or cause clots. Magnetic levitation eliminates those parts, improving blood compatibility and lowering the risk of complications such as strokes or infections.
From Lab to Clinic
Early ideas
In the early 2000s, researcher Chen Chen worked on a U.S. project called Levacor, the first fully magnetically levitated artificial heart to enter clinical trials. Although Levacor never reached the market because of size and implantation issues, Chen became convinced that magnetic levitation was the future.
Moving to China
When investors left the field, Chen returned to China and set up a team in Suzhou. At a 2009 Ministry of Science and Technology meeting, he proposed skipping the common hydrodynamic suspension approach and going straight to full magnetic levitation—a bold idea that experts liked.
First patient in China
By 2017, a critically ill patient received a BrioVAD made by BrioHealth Solutions. This marked the technology’s shift from laboratory research to real‑world use. Since then, more than 1,000 patients in China have been treated with the device.
Going Global
U.S. trials
In February 2024, the U.S. Food and Drug Administration approved BrioVAD for clinical testing, making it the first active implantable medical device from China to reach that stage. The first U.S. implant took place in November 2024 at Emory University Hospital. By April 2026, over three‑quarters of the 30 U.S. hospitals that perform the most artificial‑heart surgeries had joined the study.
European success
On June 2, 2024, BrioVAD was implanted in a patient at Utrecht University Hospital in the Netherlands. This was the device’s official entry into the European market and showed that the technology works well outside China.
Impact on Patients
Numbers and hope
Heart failure affects tens of millions worldwide. In China alone, about 13.7 million people over 35 live with the condition, and more than 1 million are in the final stage. Yet, China performs just over 1,000 heart transplants each year, leaving many patients without a donor heart.
Artificial hearts like BrioVAD are often called the “crown jewel” of medical devices because they can help large numbers of people with severe heart failure. By providing a reliable, long‑term pump, BrioVAD gives patients a chance to live longer and feel better while they wait for a transplant—or even as a permanent solution.
Real‑world results
- Over 1,000 patients have received BrioVAD in China.
- Early U.S. and European implants show stable device function and low complication rates.
- Patients report improved energy levels and fewer hospital visits.
Challenges and Future Directions
Size and speed
The current design separates the motor from the levitation unit to keep the pump small while maintaining a large rotor. Researchers continue to tweak the balance between size, rotor diameter, and spin speed to make the device even more compatible with blood.
Next steps
- Expanding clinical trials to more hospitals in the U.S., Europe, and Asia.
- Gathering long‑term data on durability and patient quality of life.
- Exploring newer materials and smarter control systems that could further reduce power consumption and noise.
Conclusion
BrioVAD shows how a simple‑sounding idea—a magnetically levitated pump the size of a ping‑pong ball—can turn into a life‑saving technology. From a bold proposal in a Beijing meeting to successful implants in China, the United States, and the Netherlands, the device illustrates the power of collaboration between government, hospitals, universities, and industry. As more patients receive this innovative heart pump, the hope is that fewer people will have to wait for a donor heart and more will enjoy healthier, longer lives.
